1. Early response evaluation by single cell signaling profiling in acute myeloid leukemia
- Author
-
Benedicte Sjo Tislevoll, Monica Hellesøy, Oda Helen Eck Fagerholt, Stein-Erik Gullaksen, Aashish Srivastava, Even Birkeland, Dimitrios Kleftogiannis, Pilar Ayuda-Durán, Laure Piechaczyk, Dagim Shiferaw Tadele, Jørn Skavland, Panagotis Baliakas, Randi Hovland, Vibeke Andresen, Ole Morten Seternes, Tor Henrik Anderson Tvedt, Nima Aghaeepour, Sonia Gavasso, Kimmo Porkka, Inge Jonassen, Yngvar Fløisand, Jorrit Enserink, Nello Blaser, Bjørn Tore Gjertsen, HUS Comprehensive Cancer Center, Department of Medicine, Clinicum, University of Helsinki, and Hematologian yksikkö
- Subjects
Cancer och onkologi ,Tumor ,Multidisciplinary ,Survival ,Regularization paths ,Protein ,3122 Cancers ,General Physics and Astronomy ,General Chemistry ,Classification ,General Biochemistry, Genetics and Molecular Biology ,Aml ,In-vivo ,Cancer and Oncology ,Mass cytometry ,High expression ,Cancer - Abstract
Aberrant pro-survival signaling is a hallmark of cancer cells, but the response to chemotherapy is poorly understood. In this study, we investigate the initial signaling response to standard induction chemotherapy in a cohort of 32 acute myeloid leukemia (AML) patients, using 36-dimensional mass cytometry. Through supervised and unsupervised machine learning approaches, we find that reduction of extracellular-signal-regulated kinase (ERK) 1/2 and p38 mitogen-activated protein kinase (MAPK) phosphorylation in the myeloid cell compartment 24 h post-chemotherapy is a significant predictor of patient 5-year overall survival in this cohort. Validation by RNA sequencing shows induction of MAPK target gene expression in patients with high phospho-ERK1/2 24 h post-chemotherapy, while proteomics confirm an increase of the p38 prime target MAPK activated protein kinase 2 (MAPKAPK2). In this study, we demonstrate that mass cytometry can be a valuable tool for early response evaluation in AML and elucidate the potential of functional signaling analyses in precision oncology diagnostics.
- Published
- 2022